BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 18349321)

  • 21. HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA).
    Mehdi O; Françoise S; Sofia CL; Urs G; Kevin Z; Bernard S; Igor S; Anabela CD; Dominique L; Eric M; Ali O
    Pancreatology; 2012; 12(2):146-55. PubMed ID: 22487525
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Breakdown of the FLT3-ITD/STAT5 axis and synergistic apoptosis induction by the histone deacetylase inhibitor panobinostat and FLT3-specific inhibitors.
    Pietschmann K; Bolck HA; Buchwald M; Spielberg S; Polzer H; Spiekermann K; Bug G; Heinzel T; Böhmer FD; Krämer OH
    Mol Cancer Ther; 2012 Nov; 11(11):2373-83. PubMed ID: 22942377
    [TBL] [Abstract][Full Text] [Related]  

  • 23. LBH589, a deacetylase inhibitor, induces apoptosis in adult T-cell leukemia/lymphoma cells via activation of a novel RAIDD-caspase-2 pathway.
    Hasegawa H; Yamada Y; Tsukasaki K; Mori N; Tsuruda K; Sasaki D; Usui T; Osaka A; Atogami S; Ishikawa C; Machijima Y; Sawada S; Hayashi T; Miyazaki Y; Kamihira S
    Leukemia; 2011 Apr; 25(4):575-87. PubMed ID: 21242994
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combinations of DNA methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung cancer cells: correlation of resistance with IFN-stimulated gene expression.
    Luszczek W; Cheriyath V; Mekhail TM; Borden EC
    Mol Cancer Ther; 2010 Aug; 9(8):2309-21. PubMed ID: 20682643
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pan-histone deacetylase inhibitor panobinostat sensitizes gastric cancer cells to anthracyclines via induction of CITED2.
    Regel I; Merkl L; Friedrich T; Burgermeister E; Zimmermann W; Einwächter H; Herrmann K; Langer R; Röcken C; Hofheinz R; Schmid R; Ebert MP
    Gastroenterology; 2012 Jul; 143(1):99-109.e10. PubMed ID: 22465428
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair.
    Maiso P; Colado E; Ocio EM; Garayoa M; Martín J; Atadja P; Pandiella A; San-Miguel JF
    Leukemia; 2009 Dec; 23(12):2265-74. PubMed ID: 19812608
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Knockdown of MTDH sensitizes endometrial cancer cells to cell death induction by death receptor ligand TRAIL and HDAC inhibitor LBH589 co-treatment.
    Meng X; Brachova P; Yang S; Xiong Z; Zhang Y; Thiel KW; Leslie KK
    PLoS One; 2011; 6(6):e20920. PubMed ID: 21687633
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Panobinostat (LBH589)-induced acetylation of tubulin impairs megakaryocyte maturation and platelet formation.
    Iancu-Rubin C; Gajzer D; Mosoyan G; Feller F; Mascarenhas J; Hoffman R
    Exp Hematol; 2012 Jul; 40(7):564-74. PubMed ID: 22381681
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The HDAC inhibitor LBH589 (panobinostat) is an inhibitory modulator of aromatase gene expression.
    Chen S; Ye J; Kijima I; Evans D
    Proc Natl Acad Sci U S A; 2010 Jun; 107(24):11032-7. PubMed ID: 20534486
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K
    Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The HDAC inhibitor, panobinostat, induces apoptosis by suppressing the expresssion of specificity protein 1 in oral squamous cell carcinoma.
    Jeon YJ; Ko SM; Cho JH; Chae JI; Shim JH
    Int J Mol Med; 2013 Oct; 32(4):860-6. PubMed ID: 23877235
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.
    Garrett LA; Growdon WB; Rueda BR; Foster R
    J Ovarian Res; 2016 Sep; 9(1):58. PubMed ID: 27633667
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Study on histone deacetylase inhibitor LBH589 induces apoptosis of multiple myeloma cells and its reversal of drug resistance mechanism].
    Zhang L; Ma YP; Jia G
    Zhonghua Xue Ye Xue Za Zhi; 2012 Nov; 33(11):926-31. PubMed ID: 23363750
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The histone deacetylase inhibitor LBH589 (panobinostat) modulates the crosstalk of lymphocytes with Hodgkin lymphoma cell lines.
    Klein JM; Henke A; Sauer M; Bessler M; Reiners KS; Engert A; Hansen HP; von Strandmann EP
    PLoS One; 2013; 8(11):e79502. PubMed ID: 24278143
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities.
    Dedes KJ; Dedes I; Imesch P; von Bueren AO; Fink D; Fedier A
    Anticancer Drugs; 2009 Jun; 20(5):321-33. PubMed ID: 19322073
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Inhibitory effect of histone deacetylase inhibitor LBH589 on multiple myeloma MM1R cells in vitro].
    Zhang L; Ma YP; Jia G; Lu YJ; Zhang L; Lu H; Chang MX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1122-6. PubMed ID: 23114131
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells.
    Catley L; Weisberg E; Kiziltepe T; Tai YT; Hideshima T; Neri P; Tassone P; Atadja P; Chauhan D; Munshi NC; Anderson KC
    Blood; 2006 Nov; 108(10):3441-9. PubMed ID: 16728695
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis.
    Korfei M; Stelmaszek D; MacKenzie B; Skwarna S; Chillappagari S; Bach AC; Ruppert C; Saito S; Mahavadi P; Klepetko W; Fink L; Seeger W; Lasky JA; Pullamsetti SS; Krämer OH; Guenther A
    PLoS One; 2018; 13(11):e0207915. PubMed ID: 30481203
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MYB down-regulation enhances sensitivity of U937 myeloid leukemia cells to the histone deacetylase inhibitor LBH589 in vitro and in vivo.
    Ye P; Zhao L; McGirr C; Gonda TJ
    Cancer Lett; 2014 Feb; 343(1):98-106. PubMed ID: 24075958
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epigenetic modulation of radiation response in human cancer cells with activated EGFR or HER-2 signaling: potential role of histone deacetylase 6.
    Kim IA; No M; Lee JM; Shin JH; Oh JS; Choi EJ; Kim IH; Atadja P; Bernhard EJ
    Radiother Oncol; 2009 Jul; 92(1):125-32. PubMed ID: 19329208
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.